Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2025 | Story Leonie Bolleurs | Photo Tanya Allen
Founders 2025
Celebrating the legacy and achievements of the UFS Business School were, from the left, front: Prof Liezel Massyn, Dr Cornelie Crous; second row: Prof Hendri Kroukamp, Prof Frederick Fourie, Prof Niel Viljoen; third row: Prof Ben Anderson, Prof Tienie Crouse; back: Prof Philippe Burger and Prof Nicolene Barkhuizen.

During a special event held at the Business School on the Bloemfontein Campus on 10 March 2025, the University of the Free State (UFS) paid tribute to the founders and those who helped build the UFS Business School to its current standing.

Those recognised include Prof Frederick Fourie, Prof Niel Viljoen, Prof Helena van Zyl, Prof Tienie Crous, Prof Hendri Kroukamp, and Prof Ben Anderson.

Prof Liezel Massyn, Associate Professor and Programme Director of the Bachelor of Management Leadership (BML) programme in the UFS Business School, welcomed the group of guests. "I remember, as a young academic growing within the faculty, seeing the five leadership principles come to life in practice. These practices demonstrate that a true leader challenges the status quo, inspires a shared vision, empowers others to take action, and leads by example. We have seen this throughout the development and growth of the Business School,” she said.

UFS Business School: a place with heart

According to Prof Philippe Burger, Dean of the Faculty of Economic and Management Sciences, it was more than a third of a century ago – with the establishment of the Centre for Management Development – that this dream of creating a business programme to support the business community through training and educating people started.

“The UFS Business School is the one business school where a whole career development opportunity is provided. One could come in with just a school qualification and do from a higher certificate to a bachelor's degree, a postgraduate diploma, an MBA, and ultimately even a PhD.”

He continued, “The BML degree offered is unique because it provides individuals in their thirties and forties – who may have missed out on higher education but are ready to step into middle management – the opportunity to get that educational background. It also provides a learning space for those pursuing a bachelor’s degree without having to sit among school leavers. It is something we treasure in the Business School,” he said.

Prof Burger believes the UFS Business School is a place with heart. “It's a place where we care about our students.”

Prof Nicolene Barkhuizen, Director of the UFS Business School, opened her speech with a quote from Theodore Roosevelt: “The more you know about the past, the better prepared you are for the future.” “The best lessons come from the past,” she said, stating that it was a great privilege to celebrate the exceptional leaders who helped build the UFS Business School.

“Your legacy lies not only in what you have achieved, but in the inspiration you're leaving behind. Your contributions have set new standards of excellence, and your legacies will continue to inspire future generations.”

Her call to action was clear, “Honour the past, not just with admiration, but with action. The true essence of leadership is not only in remembering history but also making it.

Impressive reach of the Bachelor in Managerial Leadership

For former UFS Rector and Senior Research Fellow in the Department of Economics and Finance, Prof Frederick Fourie, establishing the Business School was an incredible achievement, despite scepticism about whether the Free State needed it without a strong corporate presence. “But we persevered and created something special that primarily served the needs of businesses in the Free State,” he said.

A key milestone for him was the introduction of the Bachelor of Managerial Leadership (BML) – the vision of Prof Ben Anderson, co-founder and Executive Director of the DaVinci Institute.

Prof Fourie reminisced on the lives that have been transformed – individuals who previously did not have the opportunity to earn a degree but now do, and who go on to become managers, senior managers, directors, and even government leaders. “This makes our Business School unique,” he said, expressing his pride in the MBA and the BML.

The qualification was developed in collaboration with DePaul University in Chicago, known for its expertise in adult learning.

Prof Anderson reflected on the collaborative effort that shaped the programme and highlighted the contributions of 27 corporates and industry representatives in its design, with an emphasis on a transdisciplinary approach that integrates knowledge from various fields to provide a broad and holistic view of managerial leadership. He also acknowledged the programme’s impressive reach, extending beyond South Africa into the broader African continent. He expressed pride in the impact of its graduates in both the public and private sectors.

For Prof Niel Viljoen, the founding director of the Business School and later Vice-Rector: Operations, the greatest highlight was the opportunity to make a lasting difference in people's lives. “It is a wonderful privilege, and we were able to do it for many years and are still doing it now.” He also recalled the first course presentations – from the Management Development Programme to the first MBA class. “It was full of jokes from morning till evening. We once forgot a lecture for the MBA! Moments like those stay with you, because there’s only one first time for everything.”

He also cherished the support from the university leadership, colleagues, and the Free State business community, all of whom played an important role in the school’s success.

Prof Tienie Crous, who became Dean of the Faculty of Economic and Management Sciences in 1999, also recalled the agreement with DePaul University. As one of the first four participants in an MBA summer school there, he described how the experience broadened their perspectives and exposed them to a well-run business school. Inspired by this, they returned to teach classes themselves. The faculty also later sent senior colleagues to the United States for six weeks annually to gain industry insights.

Students making a difference

Prof Hendri Kroukamp, Dean of the Faculty of Economic and Management Sciences from 2012 to 2022, focused on defining the Business School’s niche alongside then-Director Prof Helena van Zyl. They positioned the school as a leading medium-sized institution, earning national recognition in 2016.

He said when he thinks of the Business School, the staff stand out – their professionalism and dedication to serving students. “These are not first-year students; they are adult learners. Adult learners require a completely different approach – you must, as a lecturer, ensure you are well-prepared and informed, because they will quickly pick up if you are not knowledgeable, and that can cost you credibility.”

He believes that the Business School does more than award qualifications. “We produce students who will make a difference in their communities and environments.”

Prof Helena van Zyl, the longest-serving director of the UFS Business School, was key in shaping it into a boutique business school with strong international ties. Under her leadership, the Business School achieved remarkable milestones, a testament to her impactful leadership. Beyond the UFS, she has also played an important role in the broader organisation of business schools in South Africa by leading in the promotion and advancement of the sector.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept